Literature DB >> 8648182

The opioid growth factor, [Met5]-enkephalin, and the zeta opioid receptor are present in human and mouse skin and tonically act to inhibit DNA synthesis in the epidermis.

I S Zagon1, Y Wu, P J McLaughlin.   

Abstract

Opioid peptides serve as tonically active negative growth factors in neural and non-neural cells, in addition to being neuromodulators. To investigate the involvement of opioids in homeostatic renewal of epithelial cells in the epidermis, mice were given systemic injections of the potent opioid antagonist, naltrexone (NTX) (20 mg/kg). Disruption of opioid-receptor interaction by NTX resulted in an elevation of 42 and 72% in DNA synthesis in skin from the dorsum and plantar surface of the hindfoot, respectively, within 2 h; response to NTX was dependent on the circadian rhythm in each region examined. Injection of the naturally occurring and potent opioid growth factor (OGF), [Met5]-enkephalin, at 1 mg/kg depressed DNA synthesis in the dorsum and plantar surface by 42 and 19%, respectively, within 2 h; the effects of OGF complied with the pattern of circadian rhythm in each area of skin. The decreases in labeling index evoked by OGF were blocked by concomitant administration of the opioid antagonist, naloxone (10 mg/kg); naloxone alone at the dosage utilized had no influence on cell replicative processes. In tissue culture studies, OGF and NTX respectively depressed and elevated DNA synthesis. Both OGF and its receptor, zeta, were detected in all but the cornified layer of the epidermis in murine skin from the dorsum, plantar surface, pinnae, and tail. In addition, both peptide and receptor were observed in basal and suprabasal cells of the human epidermis. These results lead to the suggestion that an endogenous opioid peptide and its receptor are present and govern cellular renewal processes in the skin in a direct manner, regulating DNA synthesis in a tonically inhibitory, circadian rhythm-dependent fashion.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8648182     DOI: 10.1111/1523-1747.ep12343712

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  8 in total

1.  Epidermal growth factor influenced by opioid peptides in immature rat uterus.

Authors:  Z Vértes; A Sándor; K A Kovács; A Oszter; J L Környei; S Kovács; M Vértes
Journal:  J Endocrinol Invest       Date:  2000-09       Impact factor: 4.256

2.  Regulated proenkephalin expression in human skin and cultured skin cells.

Authors:  Andrzej T Slominski; Michal A Zmijewski; Blazej Zbytek; Anna A Brozyna; Jackie Granese; Alexander Pisarchik; Andre Szczesniewski; Desmond J Tobin
Journal:  J Invest Dermatol       Date:  2010-12-30       Impact factor: 8.551

Review 3.  Sensing the environment: regulation of local and global homeostasis by the skin's neuroendocrine system.

Authors:  Andrzej T Slominski; Michal A Zmijewski; Cezary Skobowiat; Blazej Zbytek; Radomir M Slominski; Jeffery D Steketee
Journal:  Adv Anat Embryol Cell Biol       Date:  2012       Impact factor: 1.231

Review 4.  Opioid system and Alzheimer's disease.

Authors:  Zhiyou Cai; Anna Ratka
Journal:  Neuromolecular Med       Date:  2012-04-22       Impact factor: 3.843

5.  Dysregulation of the OGF-OGFr pathway and associated diabetic complications.

Authors:  Patricia J McLaughlin; Joseph W Sassani; Ian S Zagon
Journal:  J Diabetes Clin Res       Date:  2021

6.  The OGF-OGFr axis utilizes the p16INK4a and p21WAF1/CIP1 pathways to restrict normal cell proliferation.

Authors:  Fan Cheng; Patricia J McLaughlin; Michael F Verderame; Ian S Zagon
Journal:  Mol Biol Cell       Date:  2008-10-15       Impact factor: 4.138

7.  Temporal variation in cellular proliferation during recornification of mouse tail skin.

Authors:  R P Wilson; P J McLaughlin; C M Lang; I S Zagon
Journal:  Cell Prolif       Date:  1998 Oct-Dec       Impact factor: 6.831

8.  High expression of proenkephalin is associated with favorable outcomes in patients with gastrointestinal stromal tumors.

Authors:  Defeng Tang; Tianlong Lin; Yangyang Wang; Hui Cao
Journal:  Cancer Manag Res       Date:  2019-07-17       Impact factor: 3.989

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.